HUP9901079A2 - 5- és 6-Tagú nitrogéntartalmú gyűrűs vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

5- és 6-Tagú nitrogéntartalmú gyűrűs vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9901079A2
HUP9901079A2 HU9901079A HUP9901079A HUP9901079A2 HU P9901079 A2 HUP9901079 A2 HU P9901079A2 HU 9901079 A HU9901079 A HU 9901079A HU P9901079 A HUP9901079 A HU P9901079A HU P9901079 A2 HUP9901079 A2 HU P9901079A2
Authority
HU
Hungary
Prior art keywords
alkyl
alkylenyl
cyclic
pipe powder
powder
Prior art date
Application number
HU9901079A
Other languages
English (en)
Inventor
David A. Betebenner
Xiaoqi Chen
Stephen L. Condon
Arthur J. Cooper
Daniel A. Dickman
Steven M. Hannick
Thomas R. Herrin
Dale J. Kempf
Lawrence Kolaczkowski
Gondi N. Kumar
Jih-Hua Liu
Daniel W. Norbeck
Patricia A. Oliver
Ketan M. Patel
Daniel J. Plata
Hing Leung Sham
Peter J. Stengel
Eric J. Stoner
Jieh-Heh J. Tien
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27075785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9901079(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of HUP9901079A2 publication Critical patent/HUP9901079A2/hu
Publication of HUP9901079A3 publication Critical patent/HUP9901079A3/hu
Publication of HU223782B1 publication Critical patent/HU223782B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/42—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A találmány tárgyát az (I) általánős képletű retrővírűs prőteáz,különösen HIV prőteáz gátló hatású vegyületek képezik - a képletben R1 és R2 jelentése egymástól függetlenül rövid szénláncú alkilcsőpőrt,ciklőalkil-alkil- és aril-alkil-csőpőrt; R3 jelentése rövid szénláncú alkil-, hidrőxi-alkil- vagy ciklőalkil-alkil-csőpőrt, R4 jelentése aril- vagy heterőgyűrűs csőpőrt; R5 jelentése (A), (B), (C), (D), (E), (F), (G), (H) vagy (J) általánősképletű csőpőrt, ahől n értéke 1, 2 vagy 3, m értéke 1, 2 vagy 3, m'értéke 1 vagy 2, X jelentése -O-, -S- vagy -NH-, Y jelentése -CH2-, -O-, -S- vagy -N(R6)-, ahől R6 jelentése hidrőgénatőm, rövid szénláncúalkil-, ciklőalkil-, ciklőalkil-alkil-, aril- vagy aril-alkil-csőpőrt,Y'' jelentése -CH2- vagy -N(R6'')-, ahől R6'' jelentése hidrőgénatőm,rövid szénláncú alkil-, ciklőalkil-, ciklőalkil-alkil-, aril- vagarail-alkil-csőpőrt, Y' jelentése -N(R6')-, ahől R6' jelentésehidrőgénatőm, rövid szénláncú alkil-, ciklőalkil-, ciklőalkil-alkil-,aril- vagy aril-alkil-csőpőrt, és Z jelentése -O-, -S- vagy -NH-; és L1 jelentése -O-; -S-; -N(R7)-, ahől R7 jelentése hidrőgénatőm, rövidszénláncú alkil-, ciklőalkil- vagy ciklőalkil-alkil-csőpőrt; -O-alkilenil-csőpőrt; -S-alkilenil-csőpőrt; -S(O)-alkilenil-csőpőrt; -S(O)2-alkilenil-csőpőrt; -N(R7)-alkilenil-csőpőrt, ahől R7 jelentéseaz előzőekben megadőtt; alkilenil-O-csőpőrt; alkilenil-S-csőpőrt;alkilenil-N(R7)-csőpőrt, ahől R7 jelentése az előzőekben megadőtt;alkilenilcsőpőrt vagy alkenilenilcsőpőrt -, vagy a fenti vegyületekgyógyászati szempőntból elfőgadható sói, észterei vagy prődrőgjai. Atalálmány tárgyát képezik még a fenti hatóanyagők előállítása, azelőállítási eljárás új köztitermékei és az (I) általánős képletűhatóanyagőkat tartalmazó gyógyászati készítmények is. ŕ
HU9901079A 1995-12-13 1996-12-06 5- és 6-Tagú nitrogéntartalmú gyűrűs vegyületek, ezeket tartalmazó gyógyászati készítmények, alkalmazásuk gyógyászati készítmények előállítására és előállításuk HU223782B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57222695A 1995-12-13 1995-12-13
US08/753,201 US5914332A (en) 1995-12-13 1996-11-21 Retroviral protease inhibiting compounds
PCT/US1996/020440 WO1997021685A1 (en) 1995-12-13 1996-12-06 Retroviral protease inhibiting compounds

Publications (3)

Publication Number Publication Date
HUP9901079A2 true HUP9901079A2 (hu) 1999-09-28
HUP9901079A3 HUP9901079A3 (en) 2000-08-28
HU223782B1 HU223782B1 (hu) 2005-01-28

Family

ID=27075785

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9901079A HU223782B1 (hu) 1995-12-13 1996-12-06 5- és 6-Tagú nitrogéntartalmú gyűrűs vegyületek, ezeket tartalmazó gyógyászati készítmények, alkalmazásuk gyógyászati készítmények előállítására és előállításuk
HU0003305A HU222731B1 (hu) 1995-12-13 1996-12-06 HIV proteázt gátló tetrahidro-pirimidin-2-on-származék, azt tartalmazó gyógyszerkészítmények és eljárás a vegyület elżállítására

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0003305A HU222731B1 (hu) 1995-12-13 1996-12-06 HIV proteázt gátló tetrahidro-pirimidin-2-on-származék, azt tartalmazó gyógyszerkészítmények és eljárás a vegyület elżállítására

Country Status (20)

Country Link
US (6) US5914332A (hu)
EP (2) EP0882024B1 (hu)
JP (4) JP3170292B2 (hu)
KR (2) KR100418316B1 (hu)
CN (1) CN1207288C (hu)
AR (2) AR005053A1 (hu)
AT (1) ATE212986T1 (hu)
AU (1) AU725369C (hu)
CA (3) CA2285119C (hu)
CO (1) CO5070655A1 (hu)
CZ (5) CZ293650B6 (hu)
DE (1) DE69619140T2 (hu)
DK (1) DK0882024T3 (hu)
ES (1) ES2173341T3 (hu)
HK (2) HK1016585A1 (hu)
HU (2) HU223782B1 (hu)
IL (6) IL156236A0 (hu)
NZ (4) NZ510329A (hu)
PT (1) PT882024E (hu)
WO (1) WO1997021685A1 (hu)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
CA2335617C (en) * 1998-06-24 2009-12-15 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
AU2492500A (en) 1999-01-06 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aspartic protease inhibitors, compositions, and associated therapeutic methods
JP4753511B2 (ja) * 1999-06-04 2011-08-24 アボット・ラボラトリーズ 改良された医薬製剤
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) * 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
ES2387579T3 (es) 2000-01-19 2012-09-26 Abbott Laboratories Formulaciones farmacéuticas de inhibidores de proteasa de VIH mejoradas
MY128296A (en) * 2000-03-30 2007-01-31 Abbott Lab Crystalline pharmaceutical
CA2404687A1 (en) 2000-03-30 2001-10-11 Nemichand B. Jain Sustained release beadlets containing stavudine
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6372905B1 (en) 2000-08-31 2002-04-16 Abbott Laboratories Processes and intermediates for preparing retroviral protease inhibitors
AU2001286889A1 (en) * 2000-08-31 2002-03-13 Abbott Laboratories Process and intermediates for preparing retroviral protease inhibitors
US6911214B2 (en) * 2000-09-05 2005-06-28 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
CA2445967A1 (en) * 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US7838046B2 (en) * 2001-09-26 2010-11-23 Tampa Bay Research Institute Plant extracts and uses thereof
US6866875B2 (en) * 2001-09-26 2005-03-15 Tampa Bay Research Institute Pine cone extracts and uses thereof
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
EP1501841A2 (en) * 2002-04-26 2005-02-02 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
ITMI20021168A1 (it) * 2002-05-30 2003-12-01 Clariant Lsm Italia Spa Procedimento per la preparazione dell'acido (s)-tetraidro-a-(1-metiletil)-2-osso-1(2h)-piridinacetico
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
KR20060022647A (ko) * 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7427636B2 (en) * 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
EP1638960A4 (en) * 2003-06-27 2009-04-01 Smithkline Beecham Corp PREPARATION OF CHEMICAL COMPOUNDS
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
EP1678322A2 (en) * 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044279A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
MXPA06006609A (es) * 2003-12-11 2006-08-31 Abbott Lab Compuestos inhibidores de proteasa de vih.
ATE539074T1 (de) * 2003-12-11 2012-01-15 Abbott Lab Die hiv-protease hemmende verbindungen
US7834043B2 (en) * 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
MXPA06006899A (es) * 2003-12-22 2006-09-04 Gilead Sciences Inc Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c.
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
BRPI0418031A (pt) * 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
RS51073B (sr) 2003-12-23 2010-10-31 Tibotec Pharmaceuticals Ltd. Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata
AU2003300167B2 (en) * 2003-12-31 2010-09-16 K-Pax Vitamins, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
NZ590128A (en) 2004-07-06 2012-08-31 Abbott Lab Prodrugs of HIV protease inhibitors
ME01945B (me) 2004-07-27 2011-12-31 Gilead Sciences Inc Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
EP2457580A1 (en) * 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
WO2006100552A1 (en) * 2005-02-28 2006-09-28 Ranbaxy Laboratories Limited Processes for the preparation of lopinavir and its intermediate - (s)-tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2h)-pyrimidineacetic acid
WO2006090264A1 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited A process for the synthesis of 2-amino-5-protected amino-3-hydroxy-1, 6-diphenylhexane or a salt thereof - an intermediate for antiviral drugs
CN101088991B (zh) * 2006-06-12 2013-05-22 浙江普洛医药科技有限公司 (s)-2-(2-羰基-四氢嘧啶-1(2h)-基)-3-甲基丁酸的制备方法
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
AU2007283196A1 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
KR101518079B1 (ko) 2007-03-12 2015-05-06 넥타르 테라퓨틱스 올리고머-프로테아제 억제제 컨주게이트
FR2914920B1 (fr) 2007-04-11 2011-09-09 Clariant Specialty Fine Chem F Procede de deacetalisation d'alpha-aminoacetals.
NZ582086A (en) * 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
WO2009004653A2 (en) * 2007-07-04 2009-01-08 Matrix Laboratories Limited Process for preparing an amorphous form of (2s,3s,5s)-2-(2,6- dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-only)-3-methylbutanoyl)-amino-1,6-diphenyl hexane and product thereof
EP2188265A1 (en) * 2007-08-07 2010-05-26 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
US20100021540A1 (en) 2008-02-28 2010-01-28 Abbott Laboratories Tablets and Preparation Thereof
WO2009114151A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
WO2009121039A2 (en) * 2008-03-28 2009-10-01 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
CN102089318B (zh) * 2008-07-08 2014-05-21 吉里德科学公司 Hiv抑制剂化合物的盐
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US7820681B1 (en) 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
EP2393786B1 (en) 2009-02-06 2014-01-22 Hetero Research Foundation Novel polymorphs of lopinavir
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
EP2279728A1 (en) 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
EA025176B1 (ru) 2010-01-27 2016-11-30 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
CN101967092A (zh) * 2010-07-02 2011-02-09 厦门市亨瑞生化有限公司 2,6-二甲基苯氧乙酸的合成方法
CN101967130B (zh) * 2010-07-02 2012-12-26 厦门市亨瑞生化有限公司 利托那韦中间体的合成方法
US9174944B1 (en) 2010-12-17 2015-11-03 Abbvie Inc. Crystalline lopinavir/surfactant adducts
WO2012120541A2 (en) * 2011-03-07 2012-09-13 Hetero Research Foundation Amorphous form of lopinavir and ritonavir mixture
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
EP3415139B8 (en) 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
WO2013080148A1 (en) 2011-11-28 2013-06-06 Ranbaxy Laboratories Limited A process for the preparation of solid dispersion of lopinavir and ritonavir
EP2844231A1 (en) 2012-05-03 2015-03-11 Cipla Limited Antiretroviral composition
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
KR102161867B1 (ko) 2013-01-30 2020-10-05 스미또모 가가꾸 가부시끼가이샤 유해 절족동물의 방제 방법
CN103936679B (zh) * 2014-03-03 2016-05-11 厦门市亨瑞生化有限公司 一种2s—(1—四氢嘧啶—2—酮)—3—甲基丁酸的制备方法
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
RU2573991C1 (ru) * 2015-04-29 2016-01-27 Закрытое акционерное общество "ПЕПТЕК" Способ получения n-ацетилглюкозаминил-n-ацетилмурамил-l-аланил-d-глутаминовой кислоты
US11285142B2 (en) 2015-09-29 2022-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for identifying and treating dystonia disorders
UA118192C2 (uk) * 2015-10-22 2018-12-10 Юрій Захарович Толчеєв Противірусна фармацевтична композиція
WO2017141104A2 (en) * 2016-02-18 2017-08-24 Immune Therapeutics, Inc. Method for inducing a sustained immune response
CN106117148B (zh) * 2016-06-17 2019-04-12 厦门市蔚嘉化学科技有限公司 一种洛匹那韦的制备和纯化工艺
CN106380412A (zh) * 2016-08-31 2017-02-08 中国科学院新疆生态与地理研究所 一种合成利托那韦中间体的方法
US20200215074A1 (en) 2017-06-22 2020-07-09 Cipla Limited Method of Treatment of Cancer
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
CN107602454B (zh) * 2017-09-19 2020-12-01 佛山科学技术学院 磺酰胺类化合物及其制备方法和用途
JP2020031151A (ja) * 2018-08-23 2020-02-27 キオクシア株式会社 半導体記憶装置およびその製造方法
KR20200095934A (ko) * 2019-02-01 2020-08-11 재단법인 경기도경제과학진흥원 중동호흡기증후군 치료 또는 예방용 약학 조성물
CN111393329A (zh) * 2020-04-16 2020-07-10 安徽一帆香料有限公司 一种利托那韦和洛匹那韦中间体的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN112574027A (zh) * 2020-12-17 2021-03-30 盐城迪赛诺制药有限公司 一种2,6-二甲基苯氧基乙酸的生产工艺
WO2023118896A1 (en) 2021-12-23 2023-06-29 Subintro Limited Novel antiviral compositions comprising oleic acid
CN115784936B (zh) * 2022-12-19 2023-12-26 启东东岳药业有限公司 一种利托那韦关键中间体bdh的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751262A (en) * 1970-06-30 1973-08-07 Allied Chem Ruminant feed supplement
GB1539817A (en) * 1976-10-22 1979-02-07 Ucb Sa N-substituted lactams
EP0005689B1 (fr) 1978-05-08 1981-03-18 U C B, S.A. Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques
JPS54157586A (en) * 1978-05-30 1979-12-12 Toyama Chem Co Ltd Penicillin and cephalosporin
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4448816A (en) * 1983-08-04 1984-05-15 The Upjohn Company Compounds, compositions and process
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5472946A (en) * 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
IL90218A0 (en) * 1988-05-13 1989-12-15 Abbott Lab Retroviral protease inhibitors
IL92011A0 (en) * 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
US5164388A (en) * 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
EP0428849A3 (en) * 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
JPH06505963A (ja) 1990-11-19 1994-07-07 モンサント　カンパニー レトロウイルスプロテアーゼ阻害剤
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US5643878A (en) 1991-09-12 1997-07-01 Ciba-Geigy Corporation 5-amino-4-hydroxyhexanoic acid derivatives
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
DE69221309T2 (de) * 1991-10-11 1997-12-11 Du Pont Merck Pharma Cyclische harnstoffe und analoga verwendbar als retrovirale proteasehemmer
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DK0560268T3 (da) 1992-03-13 1995-06-12 Bio Mega Boehringer Ingelheim Substituerede pipecolinsyrederivater som HIV-proteasehæmmere
DE4213659C2 (de) * 1992-04-25 1995-06-08 Koenig & Bauer Ag Kurzfarbwerk für eine Rotationsdruckmaschine
CA2131182C (en) 1992-05-20 2005-04-26 John S. Ng Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994006775A1 (en) 1992-09-15 1994-03-31 Southern Research Institute 5,5-disubstituted hydantoins
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
PT1302468E (pt) * 1992-12-29 2009-02-13 Abbott Lab Processos e intermediários para o fabrico de compostos inibidores de protease retroviral
DE4318550A1 (de) * 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5750648A (en) 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5468733A (en) * 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
JPH08151364A (ja) 1994-02-18 1996-06-11 Nissan Chem Ind Ltd 含窒素環状化合物および除草剤
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
AU3150395A (en) * 1994-08-09 1996-03-07 Abbott Laboratories Retroviral protease inhibiting 1,2,4-triazacycloheptanes
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
WO1997017180A1 (en) 1995-11-07 1997-05-15 Lonza Inc. Halohydantoin forms and method by melt extrusion
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
AU2492500A (en) * 1999-01-06 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aspartic protease inhibitors, compositions, and associated therapeutic methods

Also Published As

Publication number Publication date
HUP9901079A3 (en) 2000-08-28
US20020004503A1 (en) 2002-01-10
US20080139811A1 (en) 2008-06-12
US6313296B1 (en) 2001-11-06
HUP0003305A3 (en) 2000-12-28
ES2173341T3 (es) 2002-10-16
KR19990072195A (ko) 1999-09-27
IL173966A0 (en) 2006-07-05
AR005053A1 (es) 1999-04-07
KR100418316B1 (ko) 2004-02-11
IL173966A (en) 2012-02-29
JP2013047266A (ja) 2013-03-07
DE69619140T2 (de) 2002-10-31
CN1207288C (zh) 2005-06-22
EP0882024A1 (en) 1998-12-09
AU725369B2 (en) 2000-10-12
EP0882024B1 (en) 2002-02-06
JP3170292B2 (ja) 2001-05-28
IL156236A (en) 2006-10-31
US6472529B2 (en) 2002-10-29
JP5597689B2 (ja) 2014-10-01
MX9804734A (es) 1998-10-31
CZ176298A3 (cs) 1998-11-11
CA2238978A1 (en) 1997-06-19
US7968707B2 (en) 2011-06-28
CN1208405A (zh) 1999-02-17
IL156237A0 (en) 2004-01-04
JP5264160B2 (ja) 2013-08-14
DE69619140D1 (de) 2002-03-21
ATE212986T1 (de) 2002-02-15
CA2509505A1 (en) 1997-06-19
CZ300131B6 (cs) 2009-02-18
DK0882024T3 (da) 2002-05-21
AU725369C (en) 2003-04-10
CA2285119C (en) 2005-09-20
EP1170289A3 (en) 2002-11-13
WO1997021685A1 (en) 1997-06-19
NZ326132A (en) 1999-11-29
CZ294246B6 (cs) 2004-11-10
CZ293650B6 (cs) 2004-06-16
EP1170289A2 (en) 2002-01-09
IL124607A0 (en) 1998-12-06
NZ338003A (en) 2005-08-26
PT882024E (pt) 2002-07-31
JP2000502085A (ja) 2000-02-22
HU222731B1 (hu) 2003-09-29
US5914332A (en) 1999-06-22
IL156236A0 (en) 2004-01-04
HU223782B1 (hu) 2005-01-28
AR025352A1 (es) 2002-11-20
CA2238978C (en) 2001-05-15
KR100404993B1 (ko) 2004-06-04
US7279582B2 (en) 2007-10-09
JP2008115189A (ja) 2008-05-22
US20030100755A1 (en) 2003-05-29
CZ296915B6 (cs) 2006-07-12
US6284767B1 (en) 2001-09-04
CZ300127B6 (cs) 2009-02-18
NZ510329A (en) 2004-02-27
HK1045303A1 (zh) 2002-11-22
AU1342297A (en) 1997-07-03
IL156237A (en) 2005-05-17
JP2001058979A (ja) 2001-03-06
JP4181291B2 (ja) 2008-11-12
IL136661A0 (en) 2001-06-14
HK1016585A1 (en) 1999-11-05
CA2285119A1 (en) 1997-06-19
CO5070655A1 (es) 2001-08-28
NZ510328A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
HUP9901079A2 (hu) 5- és 6-Tagú nitrogéntartalmú gyűrűs vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
MY102866A (en) Amide derivatives.
HUP0001285A2 (hu) Proteáz inhibitor hatású pirrolidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP9802270A2 (hu) Aril-glicin-amid-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkompozíciók és alkalmazásuk
HUP0100579A2 (hu) Amino-vajsav-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0102425A2 (hu) Gyomorsav-elválasztást gátló imidazo-piridin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0300922A2 (hu) Új vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9701596A2 (hu) 2,4-Diamino-1,3,5-triazin-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és az ezeket tartalmazó gyógyszerkészítmények
HUP0300203A2 (en) Novel cyclic amide derivatives, and pharmaceutical compositions containing same
AU4306796A (en) Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
HUP0401253A2 (hu) Dolastatin 10 származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402225A2 (hu) Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0105108A2 (hu) Amidvegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9801749A2 (hu) Nodulisporinsavszármazékok és az ezeket tartalmazó gyógyszerkészítmények
MY131193A (en) 7-(2-aminoethyl)-benzothiazolones
GB1058984A (en) Indolyl amides
HUP9700005A2 (hu) 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények
HUP9802393A2 (hu) Benzotiazolonszármazékok, alkalmazásuk, az ezeket tartalmazó gyógyszerkészítmények, eljárás a vegyületek előállítására és intermedierjeik
HUP0401018A2 (hu) 2H-1-benzopirán-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
HUP9701660A2 (hu) 10,13,15-trioxa-triciklo[9.2.1.1. 9.6]pentadekanon-származékok, eljárás ezek előállítására, és az e vegyületeket tartalmazó gyógyászati készítmények
ES8302626A1 (es) "procedimiento de preparacion de derivados carboxilato".
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
ES467069A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1-3-bencenodimetanol
HK56597A (en) 3-aminochromane derivatives procedure for their preparation and pharmaceutical compositions containing them
HUP0102522A2 (hu) 3',3'-N-bisz-helyettesített makrolid LHRH antagonista vegyületek és alkalmazásuk, eljárás előállításukra, valamint e vegyületeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20041207

GB9A Succession in title

Owner name: ABBVIE INC., US

Free format text: FORMER OWNER(S): ABBOTT LABORATORIES, US